These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 10070271

  • 1. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
    Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J.
    Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C.
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [Abstract] [Full Text] [Related]

  • 3. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
    Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C.
    Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
    [Abstract] [Full Text] [Related]

  • 4. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA.
    N Engl J Med; 1997 Aug 07; 337(6):382-7. PubMed ID: 9241127
    [Abstract] [Full Text] [Related]

  • 5. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A, Snelder AA, Mulder H.
    Am J Med; 1995 Sep 07; 99(3):235-42. PubMed ID: 7653482
    [Abstract] [Full Text] [Related]

  • 6. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.
    J Rheumatol; 2000 Oct 07; 27(10):2424-31. PubMed ID: 11036840
    [Abstract] [Full Text] [Related]

  • 7. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
    Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, Gerrits MI, van Rijn HJ.
    Ann Rheum Dis; 1997 Jun 07; 56(6):357-63. PubMed ID: 9227164
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B.
    J Clin Endocrinol Metab; 1998 Apr 07; 83(4):1128-33. PubMed ID: 9543129
    [Abstract] [Full Text] [Related]

  • 9. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
    Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I.
    Am J Med; 1997 Aug 07; 103(2):92-9. PubMed ID: 9274891
    [Abstract] [Full Text] [Related]

  • 10. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.
    Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM, Research Committee of the British Thoracic Society.
    Thorax; 2004 Sep 07; 59(9):761-8. PubMed ID: 15333852
    [Abstract] [Full Text] [Related]

  • 11. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A.
    J Rheumatol; 1994 Oct 07; 21(10):1922-6. PubMed ID: 7837160
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.
    Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI.
    Scand J Rheumatol; 1999 Jul 12; 28(3):152-6. PubMed ID: 10380836
    [Abstract] [Full Text] [Related]

  • 20. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar 12; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.